Five-Year Data Confirms Leqembi Effectively Slows Early Alzheimer's Progression

New five-year data presented at the CTAD conference show that the Alzheimer's drug Leqembi keeps 70% of patients in early disease stages, reducing advanced dementia risk by 50% and delaying cognitive decline.

Five-Year Data Confirms Leqembi Effectively Slows Early Alzheimer's Progression
Photo-illustration WireIsrael: AI Generated

New long-term tracking data presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston demonstrate that the Alzheimer's medication Leqembi delivers cumulative clinical benefits over a five-year period. According to the findings, 70% of patients receiving the treatment remained in the early stages of the disease without progressing to moderate or severe dementia. The biological treatment, a monoclonal antibody designed to clear amyloid-beta protein accumulations from the brain, was shown to reduce the risk of advancing to later disease stages by approximately 50%.

Researchers reported an estimated delay of roughly 18 months in cognitive and functional decline among patients treated with the drug. This cumulative advantage allows individuals to preserve their functional independence and cognitive capabilities significantly longer than untreated patients. Dr. Itamar Ganmor, a senior neurologist and director of the Advanced Alzheimer's Disease Treatment Service at Sheba Medical Center in Tel HaShomer, emphasized the profound impact of these findings. He noted that the therapeutic revolution which began five years ago continues to yield strong results, granting patients an average of an additional year and a half of functional independence and cutting the risk of severe dementia in half.

Patient Perspective and Early Diagnosis

For 75-year-old Sarah Ozen, who was diagnosed with Alzheimer's disease two years ago, early detection and subsequent treatment with Leqembi proved transformative. Family members first noticed minor memory lapses, prompting her to undergo medical evaluations that confirmed the early onset of the condition. Shortly after diagnosis, she began receiving the therapy.

"For me, the fact that there is no deterioration in my condition is nothing short of an extraordinary achievement and a gift for life," Ozen shared. "I continue to drive, my husband and I vacation in hotels in Israel, plan our trips abroad, and enjoy gatherings with our children, grandchildren, and friends."

Regulatory Approval and Healthcare Access

Lecanemab, marketed as Leqembi by Japanese pharmaceutical firm Eisai, received US Food and Drug Administration (FDA) approval in July 2023 and was approved in Israel a year later. It belongs to a new generation of disease-modifying therapies that also includes Donanemab, sold as Kisunla and developed by Eli Lilly and Company. Both treatments target amyloid-beta deposits in the brain to slow cognitive decline, a breakthrough made possible by advancements in early diagnostic techniques.

Despite their clinical efficacy, these innovative medications are currently administered in Israel exclusively through select medical centers in the private healthcare sector. Treatment costs range from $2,000 to $4,000 monthly, amounting to up to 13,000 shekels, forcing many patients to rely on private health insurance policies and cover substantial out-of-pocket expenses for day hospitalization and diagnostic tests. For the third consecutive year, the treatments have been submitted to the Israeli public health basket committee. Although prioritized by the Israeli Neurological Association, previous funding bids fell short due to cost considerations, leaving patients and medical professionals advocating for broader public subsidization.

Related News